Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Net Income: 2016-2025

Historic Net Income for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to -$180.4 million.

  • Ultragenyx Pharmaceutical's Net Income fell 35.12% to -$180.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$581.2 million, marking a year-over-year decrease of 3.97%. This contributed to the annual value of -$570.6 million for FY2024, which is 5.95% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Net Income of -$180.4 million as of Q3 2025, which was down 56.95% from -$115.0 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Net Income's 5-year high stood at -$73.0 million during Q3 2021, with a 5-year trough of -$245.1 million in Q3 2022.
  • For the 3-year period, Ultragenyx Pharmaceutical's Net Income averaged around -$147.6 million, with its median value being -$151.1 million (2025).
  • In the last 5 years, Ultragenyx Pharmaceutical's Net Income tumbled by 583.62% in 2021 and then soared by 34.87% in 2023.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Net Income stood at -$124.8 million in 2021, then decreased by 24.34% to -$155.2 million in 2022, then climbed by 20.60% to -$123.2 million in 2023, then decreased by 9.39% to -$134.8 million in 2024, then slumped by 35.12% to -$180.4 million in 2025.
  • Its last three reported values are -$180.4 million in Q3 2025, -$115.0 million for Q2 2025, and -$151.1 million during Q1 2025.